Skip to main content
. Author manuscript; available in PMC: 2017 Mar 21.
Published in final edited form as: Analyst. 2016 Mar 21;141(6):1939–1946. doi: 10.1039/c5an02468d

Fig. 5.

Fig. 5

Specificity of the developed assays. (A) 250 nM G16004 incubated with (i) 20 nM glucagon, (ii) 100 nM GLP-1, and (iii) 100 nM GLP-2. (B) 250 nM A42003 incubated with (i) 50 nM murine amylin (mAmy), (ii) 50 nM human amylin (hAmy), (iii) 50 nM murine CGRP (mCGRP), and (iv) 50 nM human adrenomedullin (hADM).